Pacific Shuanglin Bio-pharmacy Co., LTD (SHE: 000403)
China
· Delayed Price · Currency is CNY 23.59
+0.04 (0.17%)
Oct 10, 2024, 3:04 PM CST
Pacific Shuanglin Bio-pharmacy Co., LTD Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 | Jan '20 Jan 1, 2020 | 2019 - 2015 |
| Operating Revenue | 2,754 | 2,325 | 2,396 | 1,966 | 1,042 | 907.97 | Upgrade
|
| Other Revenue | 1.41 | 3.27 | 9.59 | 5.27 | 7.44 | 7.69 | Upgrade
|
| Revenue | 2,756 | 2,329 | 2,405 | 1,972 | 1,050 | 915.66 | Upgrade
|
| Revenue Growth (YoY) | 29.80% | -3.18% | 21.98% | 87.80% | 14.67% | 6.49% | Upgrade
|
| Cost of Revenue | 1,332 | 1,130 | 1,151 | 1,064 | 537.36 | 438.83 | Upgrade
|
| Gross Profit | 1,424 | 1,199 | 1,254 | 907.93 | 512.58 | 476.83 | Upgrade
|
| Selling, General & Admin | 451.61 | 465.81 | 565.05 | 419 | 276.16 | 256.55 | Upgrade
|
| Research & Development | 83.95 | 79.69 | 75.36 | 35.63 | 11 | 14.73 | Upgrade
|
| Other Operating Expenses | 31.93 | 21.69 | 16.8 | 15.28 | 2.52 | 7.1 | Upgrade
|
| Operating Expenses | 573.06 | 565.15 | 666.86 | 477.73 | 285.99 | 285.96 | Upgrade
|
| Operating Income | 850.45 | 633.7 | 587.01 | 430.2 | 226.59 | 190.87 | Upgrade
|
| Interest Expense | -10.63 | -9.63 | -12.03 | -10.78 | -19.31 | -21.71 | Upgrade
|
| Interest & Investment Income | 93.48 | 75.08 | 68.22 | 62.3 | 18.31 | 7.82 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.12 | -0.12 | 2.4 | -0.21 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.9 | 0.64 | -2.23 | -3.44 | -3.67 | -0.21 | Upgrade
|
| EBT Excluding Unusual Items | 935.08 | 699.67 | 643.37 | 478.06 | 221.92 | 176.76 | Upgrade
|
| Impairment of Goodwill | - | - | - | -103.18 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -38.33 | -18.97 | 4.93 | 74.21 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.13 | -0.54 | 0.44 | 0.27 | 0.02 | -0.36 | Upgrade
|
| Asset Writedown | -0.32 | -1.29 | -3.59 | -0.49 | -5.27 | -0.11 | Upgrade
|
| Legal Settlements | - | - | - | -2.14 | - | 0.01 | Upgrade
|
| Other Unusual Items | 3.08 | 9.25 | 15.24 | 11.28 | 0.52 | 12.7 | Upgrade
|
| Pretax Income | 899.63 | 688.11 | 660.39 | 458.01 | 217.19 | 189.01 | Upgrade
|
| Income Tax Expense | 104.18 | 76.64 | 72.7 | 66.47 | 34.51 | 31.17 | Upgrade
|
| Earnings From Continuing Operations | 795.45 | 611.47 | 587.69 | 391.54 | 182.68 | 157.84 | Upgrade
|
| Minority Interest in Earnings | 0.51 | 0.64 | -0.56 | -0.48 | 3.28 | 2.61 | Upgrade
|
| Net Income | 795.96 | 612.11 | 587.13 | 391.06 | 185.97 | 160.45 | Upgrade
|
| Net Income to Common | 795.96 | 612.11 | 587.13 | 391.06 | 185.97 | 160.45 | Upgrade
|
| Net Income Growth | 56.30% | 4.25% | 50.14% | 110.29% | 15.90% | 100.60% | Upgrade
|
| Shares Outstanding (Basic) | 730 | 730 | 731 | 706 | 490 | 489 | Upgrade
|
| Shares Outstanding (Diluted) | 730 | 730 | 731 | 707 | 490 | 489 | Upgrade
|
| Shares Change (YoY) | -0.15% | -0.12% | 3.37% | 44.24% | 0.23% | -0.00% | Upgrade
|
| EPS (Basic) | 1.09 | 0.84 | 0.80 | 0.55 | 0.38 | 0.33 | Upgrade
|
| EPS (Diluted) | 1.09 | 0.84 | 0.80 | 0.55 | 0.38 | 0.33 | Upgrade
|
| EPS Growth | 56.53% | 4.38% | 45.24% | 45.79% | 15.64% | 100.61% | Upgrade
|
| Free Cash Flow | 285.7 | 301.74 | 145.58 | 82.06 | 154.66 | 149.73 | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 0.41 | 0.20 | 0.12 | 0.32 | 0.31 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.080 | 0.056 | - | 0.067 | Upgrade
|
| Dividend Growth | 149.33% | 149.33% | 43.24% | - | - | - | Upgrade
|
| Gross Margin | 51.65% | 51.48% | 52.13% | 46.05% | 48.82% | 52.08% | Upgrade
|
| Operating Margin | 30.86% | 27.21% | 24.41% | 21.82% | 21.58% | 20.84% | Upgrade
|
| Profit Margin | 28.88% | 26.29% | 24.41% | 19.83% | 17.71% | 17.52% | Upgrade
|
| Free Cash Flow Margin | 10.37% | 12.96% | 6.05% | 4.16% | 14.73% | 16.35% | Upgrade
|
| EBITDA | 980.29 | 767.99 | 704.63 | 538.01 | 273.96 | 237.17 | Upgrade
|
| EBITDA Margin | 35.57% | 32.98% | 29.30% | 27.29% | 26.09% | 25.90% | Upgrade
|
| D&A For EBITDA | 129.84 | 134.29 | 117.62 | 107.82 | 47.37 | 46.3 | Upgrade
|
| EBIT | 850.45 | 633.7 | 587.01 | 430.2 | 226.59 | 190.87 | Upgrade
|
| EBIT Margin | 30.86% | 27.21% | 24.41% | 21.82% | 21.58% | 20.84% | Upgrade
|
| Effective Tax Rate | 11.58% | 11.14% | 11.01% | 14.51% | 15.89% | 16.49% | Upgrade
|
| Revenue as Reported | 2,756 | 2,329 | 2,405 | 1,972 | 1,050 | 915.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.